Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study Meeting Abstract
| Authors: | Modak, S.; Kushner, B. H.; Mauguen, A.; Castañeda, A.; Varo, A.; Gorostegui, M.; Muñoz, J. P.; Santa-Maria, V.; Basu, E. M.; Cardenas, F. I.; Pandit-Taskar, N.; Cheung, N. K. V.; Mora, J. |
| Abstract Title: | Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300032 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.10028 |
| Notes: | Meeting Abstract: 10028 -- Meeting also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
